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PRECLINICAL STUDY
eversal of Endothelial
itric Oxide Synthase Uncoupling and
p-Regulation of Endothelial Nitric Oxide Synthase
xpression Lowers Blood Pressure in Hypertensive Rats
uige Li, MD, PHD,* Klaus Witte, MD,‡ Michael August, MS,† Isolde Brausch, BS,*
te Gödtel-Armbrust, BS,* Alice Habermeier, BS,* Ellen I. Closs, PHD,* Mathias Oelze, PHD,†
homas Münzel, MD, PHD,† Ulrich Förstermann, MD, PHD*
ainz and Mannheim, Germany
OBJECTIVES We sought to examine the hypothesis that a pharmacologic up-regulation of endothelial nitric
oxide synthase (eNOS) combined with a reversal of eNOS uncoupling provides a protective
effect against cardiovascular disease.
BACKGROUND Many cardiovascular diseases are associated with oxidant stress involving protein kinase C
(PKC) and uncoupling of eNOS.
METHODS Messenger ribonucleic acid (mRNA) expression was analyzed with RNase protection assay or
quantitative real-time polymerase chain reaction, vascular nitric oxide (NO) with spin
trapping, and reactive oxygen species (ROS) with dihydroethidium fluorescence.
RESULTS Aortas of spontaneously hypertensive rats (SHR) showed an elevated production of ROS
when compared with aortas of Wistar-Kyoto rats (WKY). The aortic expression of
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits (Nox1, Nox2,
Nox4, and p22phox) was higher in SHR compared with WKY. In SHR, aortic production
of ROS was reduced by the NO synthase inhibitor NG-nitro-L-arginine methyl ester
(L-NAME), indicating eNOS “uncoupling” in hypertension. Oral treatment with the PKC
inhibitor midostaurin reduced aortic Nox1 expression, diminished ROS production, and
reversed eNOS uncoupling in SHR. Aortic levels of (6R)-5,6,7,8-tetrahydro-L-biopterin
(BH4) were significantly reduced in SHR compared with WKY. Midostaurin normalized
BH4 levels in SHR. In both WKY and SHR, midostaurin increased aortic expression of
eNOS mRNA and protein, stimulated bioactive NO production, and enhanced relaxation of
the aorta to acetylcholine. Midostaurin lowered blood pressure in SHR and, to a lesser extent,
in WKY; the compound did not change blood pressure in WKY made hypertensive with
L-NAME.
CONCLUSIONS Pharmacologic interventions that combine eNOS up-regulation and reversal of eNOS
uncoupling can markedly increase bioactive NO in the vasculature and produce beneficial
hemodynamic effects such as a reduction of blood pressure. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.0712536–44) © 2006 by the American College of Cardiology Foundation
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eitric oxide (NO) produced by endothelial nitric oxide
ynthase (eNOS) plays a protective physiological role in the
asculature (1). Besides its vasodilator effects, NO protects
he blood vessels from thrombosis by inhibiting platelet
ggregation and adhesion. In addition, endothelial NO
ossesses multiple antiatherosclerotic properties, including:
) prevention of leukocyte adhesion to vascular endothelium
nd leukocyte migration into the vascular wall; 2) decreased
ndothelial permeability, reduced influx of lipoproteins into
he vascular wall, and inhibition of low-density lipoprotein
From the *Department of Pharmacology and †Department of Internal Medicine II,
ohannes Gutenberg University, Mainz, Germany; and the ‡Institute of Pharmacol-
gy and Toxicology, Faculty of Clinical Medicine Mannheim, Ruprecht Karls
niversity Heidelberg, Mannheim, Germany. This work was supported by the
ollaborative Research Center SFB 553 (project A1 to Drs. Li and Förstermann and
roject B4 to Dr. Closs) from the DFG (Deutsche Forschungsgemeinschaft), Bonn,
ermany.e
Manuscript received December 15, 2005; revised manuscript received January 13,
006, accepted January 17, 2006.xidation; and 3) inhibition of deoxyribonucleic acid syn-
hesis, mitogenesis, and proliferation of vascular smooth
uscle cells (1). In agreement with this concept, pharma-
ologic inhibition of eNOS causes accelerated atherosclero-
is in rabbits (2) and mice (3), and deficiency in eNOS
ccelerates the development of atherosclerosis in apolipopro-
ein E-knockout mice (4).
The NO released from endothelial cells has an important
ole in controlling blood pressure. Blockade of NO synthesis
ith pharmacologic NO synthase inhibitors causes signifi-
ant peripheral vasoconstriction and elevation of blood
ressure (5,6). Mice with a disrupted eNOS gene are hyper-
ensive and lack endothelium-dependent NO-mediated
asodilation (7).
Given the beneficial effects of endothelial NO, en-
ancement of NO production by up-regulating eNOS
xpression could be of prophylactic or therapeutic inter-
st. However, overexpression of eNOS has been associ-
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June 20, 2006:2536–44 eNOS Recoupling and Up-Regulationted with enzyme dysfunction in several models. Under
hese conditions, eNOS generates reactive oxygen species
ROS) at the expense of NO (8,9). This has been referred
o as eNOS “uncoupling” (10). Interestingly, protein
inase C (PKC) inhibitors have been shown to reduce
xidative stress in the vasculature in vivo and to prevent
NOS uncoupling in a model of angiotensin II-induced
ypertension (11).
The PKC inhibitor midostaurin (4=-N-benzoyl stauro-
porine, CGP 41251, PKC-412) is an orally active small
olecule that has advanced to latter-stage clinical develop-
ent for cancer and/or other indications (12). Previous
ork from our laboratory has indicated that midostaurin
nd related compounds increase eNOS expression in cul-
ured human vascular endothelial cells independent of PKC
nhibition (13). We hypothesized that a compound with an
ction profile combining PKC inhibition and eNOS up-
egulation should markedly elevate the amount of bioactive
O in the vasculature. The current study was designed to
nvestigate this hypothesis in spontaneously hypertensive
ats (SHR) in vivo.
ETHODS
nimals and treatment with midostaurin. Male SHR and
istar-Kyoto rats (WKY) were obtained from Charles
iver Laboratories (Sulzfeld, Germany). The use of animals
n this study complies with the Guide for the Care and Use
f Laboratory Animals (National Institutes of Health) and
he German law on the protection of animals.
Midostaurin, formulated as 16% (w/w) preparation in
elucire 44/14, and Gelucire 44/14 itself were provided by
ovartis Pharma AG (Basel, Switzerland). The rats were
reated intragastrically by gavage for 5 days with 75 mg/kg/
ay midostaurin or the control substance Gelucire 44/14.
Nase protection assay for eNOS messenger ribonucleic
cid (mRNA) analyses. Total ribonucleic acid (RNA) was
solated from rat aorta by guanidinium thiocyanate-phenol-
hloroform extraction. Endothelial NO synthase mRNA
as analyzed with RNase protection assays as described
Abbreviations and Acronyms
ANOVA  analysis of variance
BH4  (6R)-5,6,7,8-tetrahydro-L-biopterin
eNOS  endothelial nitric oxide synthase
L-NAME  NG-nitro-L-arginine methyl ester
NO  nitric oxide
Nox  NADPH oxidase
PKC  protein kinase C
RNA  ribonucleic acid
ROS  reactive oxygen species
RT-PCR  real-time polymerase chain reaction
SHR  spontaneously hypertensive rats
WKY  Wistar-Kyoto ratsreviously (14). Gmmunohistochemistry analysis of eNOS protein in
orta. Aortic segments from control SHR and SHR
reated with midostaurin (75 mg/kg/day for 5 days) were
rozen in Tissue-Tek (Sakura, Heppenheim, Germany).
ryostat sections were stained for eNOS using the
nimal Research Kit (ARK, DAKO, Hamburg, Ger-
any). The mouse monoclonal anti-eNOS antibody was
rom BD Transduction Laboratories (Heidelberg, Ger-
any). Briefly, the primary mouse antibody was biotinylated
nd incubated with the tissue specimens, followed by an
ncubation with streptavidin-peroxidase. The reaction
as visualized with 3,3=-diaminobenzidine.
easurement of aortic ROS production by L-012 chemi-
uminescence. Vascular ROS production was determined
sing the luminol derivative L-012 [8-amino-5-chloro-7-
henylpyridol[3,4-d]pyridazine-1,4(2H,3H)dione] (15–
7). Briefly, aortas from untreated SHR, control WKY,
idostaurin-treated SHR (75 mg/kg/day for 5 days), and
idostaurin-treated WKY were isolated, cut into 3-mm
ings, and incubated for 30 min at 37°C in 96-well plates in
anks’ balanced salt solution (PAA Laboratories, Cölbe,
ermany) containing 100 mol/l L-012, with or without
he NO synthase inhibitor NG-nitro-L-arginine methyl
ster (L-NAME, 1 mmol/l). Then, L-012–derived chemi-
uminescence was measured using a Microplate Luminom-
ter (Berthold, Bad Wildbad, Germany). The photon
ounts were normalized for the dry weight of aortic tissue.
easurement of vascular superoxide production by
ihydroethidium fluorescence. The oxidative fluorescent
ye dihydroethidium was used to evaluate the amount of
uperoxide in situ as described previously (11,18). After
reatment with midostaurin (75 mg/kg/day) for 5 days,
ortas were harvested and 10 m frozen sections were
repared. The sections were then allowed to thaw and were
ncubated with 10 mol/l dihydroethidium. Dihydro-
thidium is cell permeable and reacts with superoxide to
orm ethidium, which in turn intercalates in the deoxyribo-
ucleic acid, thereby exhibiting a red fluorescence. Photo-
raphs were taken using a fluorescent microscope at an
xcitation wavelength of 520 nm and an emission wave-
ength of 610 nm. To analyze the potential contribution of
NOS to ROS production, some sections were preincubated
ith L-NAME (1 mmol/l) for 30 min. Autofluorescence of
he elastic laminae was detected using a green filter.
T-PCR for mRNA expression of NADPH oxidase
ubunits. The mRNA expression of NADPH oxidase
Nox) subunits was analyzed with quantitative RT-PCR
sing an iCycler iQ System (Bio-Rad Laboratories,
unich, Germany). Total RNA was isolated from aortas
f WKY and SHR. We used 0.5 g of total RNA for
T-PCR analysis with the QuantiTec probe RT-PCR
it (Qiagen, Hilden, Germany). Sequences of used prim-
rs and of the TaqMan probes were (forward, reverse, and
robe) GCTGGCCTTACTGGAGTGGTC, TCCT-
CGGATAAACTCCATAGC, and CCACTGTGG-
C
G
G
T
C
C
T
G
C
G
T
G
M
t
m
a
H
t
m
u
c
m
t
t
F
s
7
i
a
l
w
T
2538 Li et al. JACC Vol. 47, No. 12, 2006
eNOS Recoupling and Up-Regulation June 20, 2006:2536–44TTTGGTTCTCATGGTAACTT for Nox1; CTTCTT-
GGTCAGCACTGGC, GCAGCAAGATCA-
CATGCAG, and CACCTGCAGCCTGCCTGAATT-
CA for Nox2 (gp91phox); CTGTCCTGAACCT-
AACTGCAG, TGTGATCCGCGAAGGTAAGC, and
TTTTACCCATGTGCCGCACAGTCCT for Nox4;
ACCTGACCGCTGTGGTGAAG, GCAGTAAGTG-
AGGACAGCCC, and TGTTCGGGCCCCTCAC-
AGAAATTAC for p22phox; and TTCTTGTGCAGT-
CCAGCC, CGTCCGATACGGCCAAATC, and
CTCATAGACAAGATGGTGAAGGTCGGTGT for
APDH.
igure 1. Midostaurin reduces aortic production of reactive oxygen spec
pontaneously hypertensive rats (SHR). Aortas were isolated from SHR or
5 mg/kg/day for 5 days). Production of reactive oxygen species (ROS) fr
n the absence or presence of the NOS inhibitor L-NAME (1 mmol/l) (A
ortas from six different animals (**p  0.01 compared with any other c
east-significant-difference test). (B) ROS production in SHR aorta as dete
ith or without L-NAME (1 mmol/l) and then labeled with dihydroethidium, w
he autofluorescence of the elastic laminae is in green. Arrows indicate the eneasurement of vascular content of (6R)-5,6,7,8-
etrahydro-L-biopterin (BH4). After treatment with
idostaurin (75 mg/kg/day) for 5 days, aortas were isolated
nd homogenized in ice-cold lysis buffer (0.1 mol/l Tris-
Cl, pH 7.8, containing 5 mmol/l ethylenediamin tetraace-
ic acid, 0.3 mol/l KCl, 5 mmol/l 1,4-dithioerythritol, 0.5
M Pefabloc, and 0.01% saponin). Samples were oxidized
nder either acidic conditions (with 0.2 mol/l HCl
ontaining 50 mmol/l I2) or alkaline conditions (with 0.2
ol/l NaOH containing 50 mmol/l I2). Biopterin con-
ent was assessed using high-performance liquid chroma-
ography with fluorescence detection (350 nm excitation,
d reverses endothelial-type nitric oxide synthase (eNOS) uncoupling in
ar-Kyoyo (WKY ) rats treated orally with vehicle or midostaurin (Mido,
rtic rings (3 mm) was determined by L-012–derived chemiluminescence
h column represents ROS determinations (mean  SEM) obtained with
, tested by analysis of variance (ANOVA) followed by Fisher protected
ith fluorescent microscopy using dihydroethidium. Aortas were incubatedies an
Wist
om ao
). Eac
olumn
cted which produces a red fluorescence when oxidized to ethidium by superoxide.
dothelium.
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June 20, 2006:2536–44 eNOS Recoupling and Up-Regulation50 nm emission). BH4 concentration was calculated as
mol/g protein by subtracting the biopterin peak result-
ng from alkaline oxidation (accounting for BH2) from
he biopterin peak resulting from acidic oxidation (ac-
ounting for both BH2 and BH4).
pin trapping of aortic NO using colloid Fe(DETC)2.
egments from rat thoracic aorta (10 mm) were cut into
-mm rings and incubated at 37°C for 30 min in Krebs
olution in the presence of 1 mol/l acetylcholine and 200
mol/l colloid Fe(DETC)2 as described previously (11,19).
lectron paramagnetic resonance studies were performed on
tabletop X-band spectrometer Miniscope (Magnettech,
erlin, Germany). Recordings were made at 77 K using a
ewar flask (Wilmad, Buena, New Jersey). Instrument
ettings were 10 mW of microwave power, 1 mT of
mplitude modulation, 100 kHz of modulation frequency,
nd 60 s of sweep time. Samples were scanned 10 times.
etermination of total NO synthesis as nitrite/nitrate in
at serum. Oxidation products of NO (nitrite and nitrate)
ere assayed in rat serum as a measure of total NO synthesis
sing a NOA 280 Nitric Oxide Analyzer (Sievers, Boulder,
olorado) after enzymatic reduction with nitrate reductase
20,21).
rgan chamber experiments using rat aorta. After 5 days
f treatment with midostaurin or Gelucire 44/14, aortas
ere isolated from 12 WKY and 18 SHR, cut into 3-mm
ings, set up in organ chambers, and precontracted with 100
igure 2. Midostaurin reduces the messenger ribonucleic acid (mRNA)
xpression of the NADPH oxidase subunit Nox1 in SHR. Total RNA was
solated from the aortas of 18 SHR and 12 WKY (receiving vehicle or 75
g/kg/day midostaurin for 5 days, Mido). Quantitative real-time poly-
erase chain reaction was performed to analyze the mRNA expression of
he NADPH oxidase (Nox) subunits Nox1, Nox2 (gp91phox), Nox4, and
22phox. Each column represents data (mean  SEM) obtained with
ortas from six to nine different animals (**p  0.01, ***p  0.001, tested
y ANOVA followed by Fisher protected least-significant-difference test).
bbreviations as in Figure 1.mol/l norepinephrine. Endothelium-dependent vasodila-
f
tor responses to acetylcholine were determined in the
bsence or presence of L-NAME (1 mmol/l).
elemetric measurement of blood pressure. In 18 con-
cious WKY and 18 SHR, systolic and diastolic blood
ressure as well as heart rate were measured telemetrically
ith implanted transmitter-coupled pressure transducers in
he abdominal aorta as described (22). The rats first received
elucire 44/14 (vehicle) for one week and, after a washout
eriod of another week, midostaurin for an additional week.
dditional WKY were treated with L-NAME 24 mg/kg/
ay before and during midostaurin treatment.
tatistics. Analysis of variance (ANOVA) for repeated
easures was used to analyze the curves for the vascular
elaxation studies in the organ bath. Other differences were
ested for statistical significance by ANOVA followed by
isher protected least-significant-difference test.
ESULTS
nhanced oxidative stress and increased vascular ex-
ression of NADPH oxidases in SHR compared with
KY. Compared with WKY, SHR produced more
OS in the vasculature (Fig. 1A). This increased oxida-
ive stress can in part be explained by an enhanced
xpression of NADPH oxidases Nox1, Nox2, Nox4, and
22phox in the aorta of SHR compared with WKY (Fig.
). In SHR, an additional contribution to ROS production
ame from uncoupled eNOS, because L-NAME markedly
educed ROS production in these hypertensive rats (Figs.
A and 1B). In WKY, we found no evidence for eNOS
ncoupling because L-NAME did not reduce aortic ROS
roduction (Fig. 1A).
igure 3. Midostaurin increases the vascular content of (6R)-5,6,7,8-
etrahydro-L-biopterin (BH4) in SHR. BH4 levels were measured by
igh-performance liquid chromatography in aortas from 18 SHR and 12
KY (receiving vehicle or 75 mg/kg/day midostaurin for 5 days, Mido).
ach column represents data (mean SEM) obtained with aortas from six
o nine different animals (*p  0.05, ***p  0.001, tested by ANOVA
ollowed by Fisher protected least-significant-difference test). Abbrevia-
ions as in Figure 1.
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eNOS Recoupling and Up-Regulation June 20, 2006:2536–44reatment with midostaurin reduced aortic ROS pro-
uction, diminished vascular Nox1 expression, and re-
ersed eNOS uncoupling in SHR. Treatment with
idostaurin (75 mg/kg/day) for 5 days had no effect on
ortic ROS production in WKY but normalized the ele-
ated ROS levels seen in SHR (Fig. 1).
igure 4. Midostaurin increases eNOS mRNA expression in the aorta of
HR and WKY rats. Rats were treated orally with vehicle or midostaurin
Mido, 75 mg/kg/day) for 5 days. Endothelial nitric oxide synthase
RNA expression in aortas was analyzed with RNase protection assay.
anels A and C show representative gels of an RNase protection assay.
anels B and D show the results of densitometric analyses. Each column
mean  SEM) represents data obtained with aortas from nine different
ats (***p 0.001 compared vehicle, tested by ANOVA followed by Fisher
rotected least-significant-difference test). Abbreviations as in Figures 1
nd 2.
igure 5. Midostaurin increases eNOS protein expression in the aorta of S
idostaurin (SHRMido, 75 mg/kg/day) for 5 days. Endothelial nitric oxintibody. In the negative control, mouse immunoglobulin G was used instead of
bbreviations as in Figure 1.In WKY rats, midostaurin also had no significant effect
n the expression of NADPH oxidase (Fig. 2), which
irrored its missing effect on aortic ROS production.
In contrast, midostaurin treatment of SHR for 5 days (75
g/kg/day) markedly reduced mRNA expression of Nox1
Fig. 2), a major source of ROS in the vasculature
11,23,24). Midostaurin had no significant effect on the
xpression of Nox2, Nox4, or p22phox in SHR (Fig. 2).
In midostaurin-treated SHR, L-NAME no longer re-
uced aortic ROS production (Fig. 1), demonstrating a
eversal of eNOS uncoupling by the PKC inhibitor.
reatment with midostaurin increased vascular BH4
evels in SHR. The aortic levels of BH4 were lower in SHR
han in WKY. Midostaurin treatment (75 mg/kg/day) for 5
ays significantly increased the BH4 content in the aorta of
HR (Fig. 3).
reatment of WKY rats and SHR with midostaurin
ncreased eNOS expression. Oral treatment with 75 mg/
g/day midostaurin for 5 days resulted in a significant increase
n eNOS mRNA expression in aorta compared with control
ats, as determined with RNase protection assay (Fig. 4). This
as true for both SHR and WKY. Immunohistochemical
nalyses demonstrated the up-regulation of eNOS protein in
ortic endothelium of SHR (Fig. 5).
reatment with midostaurin increased aortic NO pro-
uction and serum nitrite/nitrate levels. Electron para-
agnetic resonance studies showed increased amounts of
ctive NO in the aorta of SHR treated with midostaurin (75
g/kg/day orally for 5 days) (Figs. 6A and 6B). Accordingly,
erum levels of nitrite/nitrate, the oxidation products of NO,
ere also increased by midostaurin (Fig. 6C). The effect in
KY was similar to SHR (Fig. 6C).
idostaurin increased endothelium-/eNOS-dependent
elaxation of the aorta of WKY and SHR. In organ
hamber experiments with aortas from WKY or SHR,
idostaurin enhanced the potency and efficacy of acetyl-
holine in inducing endothelium-mediated relaxations.
he NOS inhibitor L-NAME completely abolished
elaxations of control and midostaurin-treated aortas.
igure 7 shows the responses of SHR aortas; aortas from
KY showed closely similar results (n  6, not shown).
Six SHR were treated orally with vehicle (SHR) and six other SHR with
thase was stained immunohistochemically with an anti-eNOS monoclonalHR.
de synthe anti-eNOS antibody. Micrographs are shown in 400 magnification.
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June 20, 2006:2536–44 eNOS Recoupling and Up-RegulationWhen midostaurin (0.1 to 10 mol/l) was added acutely
o aortas from untreated SHR in organ chambers, it had no
ffect on vascular tone (n  4, not shown).
idostaurin treatment lowered blood pressure in SHR
nd WKY, but not in L-NAME-treated WKY. Vehicle
Gelucire 44/14) treatment had no effect on blood pressure
evelopment in SHR (Fig. 8A; a slight increase was also
een in untreated SHR). Treatment with midostaurin re-
ulted in a reduction of blood pressure (Fig. 8A). Blood
ressure dropped significantly within 24 h of the first dose.
he reduction reached a maximum after 48 h and was
aintained at this level. This decrease in blood pressure
eemed to result from eNOS recoupling and enhanced
NOS expression rather than direct activation of the en-
yme, because acute infusion of midostaurin into SHR (for
0 min) produced no decrease in blood pressure (data not
hown). The effect of long-term treatment with midostaurin
n blood pressure was reversible; blood pressure increased
gain when midostaurin was withdrawn (Fig. 8A).
idostaurin treatment also lowered blood pressure in WKY,
lthough to a lesser extent (Fig. 8B).
In additional experiments, hypertension was induced in
KY with L-NAME. When midostaurin was adminis-
ered in the presence of L-NAME, the compound had no
ffect on blood pressure (Fig. 8C).
ISCUSSION
he present study demonstrates that a compound with the
ombined properties of PKC inhibition and eNOS up-
egulation leads to a marked elevation of bioactive NO with
he expected sequels of vasodilation and blood pressure
igure 7. Midostaurin enhances vasodilator response of SHR aorta.
HR were treated orally with vehicle (Co) or midostaurin (Mido, 75
g/kg/day) for five days and aortic rings were prepared. Vasodilator
esponse to acetylcholine was assayed in organ chambers after precon-
raction with 100 nmol/l norepinephrine in the absence or presence of
he NOS inhibitor L-NAME (1 mmol/l). Symbols represent mean 
EM of experiments performed with nine different aortas each (**p 
.01, compared with Co, tested by ANOVA for repeated measures).
bbreviations as in Figure 1.igure 6. Midostaurin increases NO production in the aorta and serum
evels of nitrite/nitrate in SHR and WKY. SHR and WKY were treated
rally with vehicle or midostaurin (Mido, 75 mg/kg/day) for 5 days.
ioactive NO in SHR aorta was assessed by electron paramagnetic
esonance spin trapping technique using colloid Fe(DETC)2. Serum
itrite/nitrate was measured with an NO analyzer. (A) Original spectra.
rrows indicate the typical triplet caused by NO-Fe(DETC)2. (B)
uantification of NO-trapping experiments from the aortas of 12 animals
ormalized to aortic area and incubation time. (C) Serum levels of
itrite/nitrate in 36 SHR and 24 WKY. Columns represent mean SEM
***p  0.001, tested by ANOVA followed by Fisher protected least-eduction in SHR.
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eNOS Recoupling and Up-Regulation June 20, 2006:2536–44Cardiovascular diseases, such as hypertension, hypercho-
esterolemia, and atherosclerosis, are often associated with
KC activation and increased oxidative stress in the vascu-
ature (10). Under these conditions, eNOS can become
ysfunctional and uncoupled, producing ROS instead of
O. Such an eNOS uncoupling has been shown to be the
ajor mechanism for endothelial dysfunction observed in
ascular diseases, including angiotensin II-induced hyper-
ension, streptozotocin-induced diabetes, and nitrate toler-
nce (11,14,25). Oxidation of BH4 owing to vascular oxidative
tress has been shown to cause BH4 deficiency (26). BH4 is an
ssential cofactor for eNOS, and a lack of BH4 seems to play
igure 8. Midostaurin lowers blood pressure in SHR and WKY, but not
as measured telemetrically in conscious rats with implanted transmitter
reated orally with vehicle for 1 week. After recovery for another week, rats
ndicate the single doses. Symbols represent mean SEM of three experim
Mido, 75 mg/kg/day) for 7 days. Symbols represent mean  SEM of nin
24 mg/kg/day, in the drinking water) from day 2 through day 7. Midosta
ymbols represent mean SEM of 9 rats. (*p 0.05, **p 0.01 ***p 0
ollowed by Fisher protected least-significant-difference test.) Abbreviationcrucial role in eNOS uncoupling (27–29). tNumerous enzyme systems can potentially produce ROS
n the vessel wall; however, four enzyme systems seem to
redominate. These include the NADPH oxidases, xan-
hine oxidase, mitochondrial sources, and uncoupled eNOS
30). Interestingly, there appears to be substantial interplay
mong these sources, such that activation of one can
nhance activity of others. Especially the Nox isoforms seem
o be upstream of an activation of other ROS-producing
nzymes, because the Nox-derived superoxide has been
mplicated in the activation of xanthine oxidase and in
NOS uncoupling (31).
In the current study, we analyzed the expression of Nox in
NAME–treated WKY. Systolic and diastolic blood pressure (SBP, DBP)
led pressure transducers. (A) Spontaneously hypertensive rats were first
treated orally with midostaurin (Mido, 75 mg/kg/day) for 7 days. Arrows
of six rats each. (B) Wistar-Kyoto rats were treated orally with midostaurin
s. (C) Wistar-Kyoto rats were treated with the NOS inhibitor L-NAME
Mido, 75mg/kg/day) was administrated orally from day 4 through day 7.
compared with the value before midostaurin treatment, tested by ANOVA
in Figure 1.in L-
-coup
were
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urin (
.001,he aorta of SHR and found that Nox1, Nox2, Nox4, and
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June 20, 2006:2536–44 eNOS Recoupling and Up-Regulation22phox were up-regulated compared with WKY. This
ay be responsible for the observed oxidative stress in these
ypertensive animals. An up-regulation of p22phox in SHR
as also been reported in a previous study (32).
In SHR, but not in WKY, treatment with midostaurin
arkedly reduced the (enhanced) expression of Nox1, but
eft the other Nox isoforms (subunits) unchanged. Nox1
own-regulation by midostaurin seems to be PKC-
ependent, because a similar down-regulation has been
bserved with other PKC inhibitors such as chelerythrine
11). Nox1 has been established as a major source of ROS
n animal models of hypertension (11,23,24). Accordingly,
n the current study the down-regulation of Nox1 by
idostaurin was associated with a reduced aortic ROS
roduction and a reversal of eNOS uncoupling in SHR.
he main reason for this “recoupling” of eNOS could be an
levation of vascular BH4 content (Fig. 3) owing to reduced
H4 oxidation.
Interestingly, midostaurin also increases eNOS gene ex-
ression. We have previously demonstrated the same effect
n cultured human endothelial cells. Midostaurin-induced
NOS expression is a transcriptional event, because
idostaurin increases eNOS promoter activity and has no
ffect on eNOS mRNA stability (13). The mechanism
nderlying the midostaurin-induced stimulation of eNOS
romoter activity is not clear at this time, but it is indepen-
ent of the inhibitory effect of the compound on PKC,
AMP-dependent kinase (PKA), cGMP-dependent kinase
PKG), or tyrosine kinases (13). Also, Rho kinase is unlikely
o be involved. Rho kinase negatively regulates eNOS
RNA stability by changes in the endothelial actin cy-
oskeleton (33). Because eNOS mRNA stability is not
hanged by midostaurin, the effect of midostaurin on eNOS
xpression is likely to be independent of Rho kinase.
Here we show that such an eNOS up-regulation also
ccurs in vivo. This also contributes to the observed increase
n NO production in vivo and the enhanced vasodilator
esponse to acetylcholine ex vivo. The blood pressure
eduction seen in SHR is mediated by a functional and
p-regulated eNOS, because the effect is not seen in
-NAME-treated WKY. Also, in apolipoprotein E-knockout
ice, treatment with midostaurin increased the expression
f eNOS in the vasculature, and the eNOS enzyme was in
functional state (34). The up-regulation of a functional
NOS enzyme was associated with a dilation of resistance
rterioles, which is in agreement with the blood pressure
owering effect of midostaurin (34).
Owing to the antithrombotic, antiatherosclerotic, and
ntihypertensive properties of endothelial NO, the eNOS
nzyme could be an interesting target for the prevention or
herapy of cardiovascular diseases (10,35). However, a
imple up-regulation of eNOS gene expression and/or
nzyme activity could be detrimental, because eNOS is
ften uncoupled under pathologic conditions. An up-
egulation of uncoupled eNOS would boost the pre-existing cxidative stress, as has been reported for eNOS-transgenic
ice on an apolipoprotein E-knockout background (36).
A more realistic strategy for eNOS-related treatment of
ascular disease may be the reversal of eNOS uncoupling.
idostaurin is a compound that achieves this goal by
nhibiting PKC. We have previously shown in other animal
odels that PKC inhibition successfully reduced ROS
roduction, reversed eNOS uncoupling, and reestablished
ndothelial function (11,14). In a rat model of angiotensin
I-induced hypertension, we used the PKC inhibitor chel-
rythrine (11), and in the rat model of streptozotocin-
nduced diabetes, we used midostaurin at a dose of 10
g/kg/day (14). This dose is high enough to inhibit PKC
ut insufficient to up-regulate eNOS expression.
In cardiovascular diseases, eNOS is often found up-
egulated (10). This can be considered an attempt of the
rganism to compensate for NO deficiency. The attempt
sually fails because the up-regulated eNOS uncouples.
ctivation of PKC seems to play a crucial role in eNOS
p-regulation in disease states (as it does in eNOS uncou-
ling, as shown earlier) (10,37). Consequently, the PKC
nhibitors, although restoring eNOS enzymatic function,
educed eNOS expression (14). The result was a functional
NOS but low NO production (14).
This predicament is not encountered with midostaurin.
t higher doses, the compound increases eNOS expression
n addition to restoring eNOS functionality (via PKC
nhibition) (13). Both the (PKC-independent) eNOS up-
egulation and the (PKC-dependent) eNOS “recoupling”
ontribute to the enhanced production of bioactive NO and
hus the beneficial effects of midostaurin in vascular patho-
hysiology. In three previous in vivo studies, three different
KC inhibitors other than midostaurin have been used
11,38,39). None of these compounds had any effect on
NOS expression (13,37), and none changed vascular tone
r blood pressure. In a study by Chrissobolis and Sobey (38)
ith chronically hypertensive rats, PKC inhibition with Ro
1-8220 did not significantly affect basilar artery diameter;
n a rat diabetes model, PKC inhibition with LY333531 did
ot reduce hypertension, although it attenuated the progres-
ion of diabetic nephropathy (39).
In conclusion, we postulate the following sequence of
vents for the action of midostaurin in SHR. Midostaurin
educes Nox1 expression (Fig. 2) and thus ROS generation
Fig. 1). This in turn enhances BH4 levels (Fig. 3) and lets
NOS regain its normal function (“recoupling”) (Fig. 1).
ioactive NO is being produced again, and its production is
urther increased by the concurrent stimulation of eNOS
ene expression (Figs. 4 and 5). This combination of effects
eads to blood pressure reduction in SHR.
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